VistaGen <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Reports Q1 Fiscal Year 2026 Results: Net Loss Widens to $15.1M, R&D Expenses Increase by 54%
VistaGen Therapeutics Inc. has announced its financial results for the fiscal year 2026 first quarter, which ended on June 30, 2025. The company reported a net loss of $15.1 million, an increase from the $10.7 million net loss in the same period the previous year. Research and development expenses rose to $11.7 million, up from $7.6 million year-over-year, primarily due to increased costs associated with the U.S. registration-directed PALISADE Program for fasedienol in social anxiety disorder (SAD). General and administrative expenses slightly decreased to $4.4 million from $4.6 million in the prior year. As of June 30, 2025, VistaGen held cash, cash equivalents, and marketable securities totaling $63.2 million. The company continues to advance its intranasal pherine pipeline, targeting treatments in psychiatry, women's health, and cancer supportive care. Topline results from the PALISADE-3 Phase 3 trial of fasedienol for the acute treatment of SAD are expected in the fourth quarter of 2025, with results from the PALISADE-4 Phase 3 trial anticipated in the first half of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VistaGen Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250807014578) on August 07, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.